These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11834769)

  • 1. Costs of aspirin and statins in general practice.
    Drummond A; Kwok S; Morgan J; Durrington PN
    QJM; 2002 Jan; 95(1):23-6. PubMed ID: 11834769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing community dyspepsia drug costs: a controlled trial.
    Valori RM; Brown CM; Strangeways P; Bradburn M
    Gut; 2001 Oct; 49(4):495-501. PubMed ID: 11559645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
    Kübler W
    Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of prescribing costs for ulcer-healing drugs and upper gastrointestinal endoscopy in general practice.
    Asante MA; Mendall MA; Bland JM; Northfield TC
    Eur J Gastroenterol Hepatol; 1998 Jul; 10(7):589-93. PubMed ID: 9855084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006.
    Lin YC; Yang CC; Chen YJ; Peng WC; Li CY; Hwu CM
    J Chin Med Assoc; 2012 Nov; 75(11):567-72. PubMed ID: 23158034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.
    Morant SV; McMahon AD; Cleland JG; Davey PG; MacDonald TM
    Br J Clin Pharmacol; 2004 Feb; 57(2):188-98. PubMed ID: 14748818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of inadequate prescriptions for hypolipidaemic drugs. VICAF Group.
    Ballesteros LC; Fernández San Martín MI; Sanz Cuesta T; Escortell Mayor E; López Bilbao C
    Pharmacoeconomics; 2001; 19(5 Pt 1):513-22. PubMed ID: 11465310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R; Pandor A; Stevens J; Rees A; Rafia R
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort.
    Major R; Shepherd D; Warwick G; Brunskill N
    Nephron; 2016; 133(1):15-22. PubMed ID: 27160883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice.
    Cooper AL; Langworthy H; Porter S
    Int J Clin Pract; 2000 Jun; 54(5):287-92. PubMed ID: 10954954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prescribing of proton pump inhibitors in general practice.
    Hungin AP; Rubin GP; O'Flanagan H
    Br J Gen Pract; 1999 Jun; 49(443):451-3. PubMed ID: 10562744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, sex, and temporary resident originated prescribing units (ASTRO-PUs): new weightings for analysing prescribing of general practices in England.
    Roberts SJ; Harris CM
    BMJ; 1993 Aug; 307(6902):485-8. PubMed ID: 8305014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
    Tonstad S; Rosvold EO; Furu K; Skurtveit S
    J Intern Med; 2004 Apr; 255(4):494-502. PubMed ID: 15049884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of prescribed and non-prescribed medication for dyspepsia.
    Krol N; Muris JW; Schattenberg G; Grol R; Wensing M
    Scand J Prim Health Care; 2004 Sep; 22(3):163-7. PubMed ID: 15370793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
    Goldberg A; Gerkin RD; Young M
    Dig Dis Sci; 2015 Jul; 60(7):2058-62. PubMed ID: 25680872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study.
    Gumbs PD; Verschuren WM; Mantel-Teeuwisse AK; de Wit AG; Hofman A; Trienekens PH; Stricker BH; de Boer A; Klungel OH
    Drugs Aging; 2006; 23(9):733-41. PubMed ID: 17020397
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.